Valuation: Amarin Corporation plc

Market Cap 343M 300M 276M 257M 488M 32.68B 495M 3.31B 1.29B 16.07B 1.29B 1.26B 55.36B P/E 2026 *
-468x
P/E 2027 * 298x
Enterprise Value 169M 148M 136M 127M 241M 16.13B 244M 1.63B 635M 7.93B 636M 622M 27.32B EV / Sales 2026 *
0.93x
EV / Sales 2027 * 0.81x
Free-Float
89.38%
Yield 2026 *
-
Yield 2027 * -
1 day-0.71%
1 week+0.72%
Current month+2.19%
1 month+15.70%
3 months+11.11%
6 months+20.69%
Current year+17.65%
1 week 13.6
Extreme 13.6
14.1
1 month 11.8
Extreme 11.8
14.1
Current year 11.2
Extreme 11.2
14.1
1 year 11.2
Extreme 11.2
17.2
3 years 5.92
Extreme 5.92
25.2
5 years 5.92
Extreme 5.92
101.2
10 years 5.92
Extreme 5.92
540
Manager TitleAgeSince
Chief Executive Officer 63 03/06/2024
Director of Finance/CFO 42 22/10/2024
Compliance Officer 56 14/11/2023
Director TitleAgeSince
Director/Board Member 63 03/06/2024
Director/Board Member 43 27/02/2023
Director/Board Member 67 27/02/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%+0.72% - - 343M
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.51%+8.57%+54.24%+147.40% 27.28B
Weighted average by Cap. +2.46%+6.47%+58.32%+136.98%

Financials

2026 *2027 *
Net sales 182M 159M 146M 136M 259M 17.35B 263M 1.76B 683M 8.53B 684M 669M 29.39B 193M 169M 155M 144M 274M 18.37B 278M 1.86B 723M 9.03B 724M 709M 31.11B
Net income -15.02M -13.13M -12.07M -11.25M -21.34M -1.43B -21.66M -145M -56.33M -703M -56.39M -55.18M -2.42B 22.13M 19.35M 17.78M 16.57M 31.43M 2.11B 31.91M 213M 82.98M 1.04B 83.07M 81.29M 3.57B
Net Debt -174M -152M -140M -130M -247M -16.55B -251M -1.68B -652M -8.14B -653M -639M -28.04B -187M -164M -151M -140M -266M -17.85B -270M -1.81B -703M -8.77B -704M -689M -30.24B
Logo Amarin Corporation plc
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Employees
80
Date Price Change
03/07/26 €14.00 -0.71%
02/07/26 €14.10 +3.68%
01/07/26 €13.60 -0.73%
30/06/26 €13.70 -2.14%
29/06/26 €14.00 +0.72%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
16.37USD
Average target price
12.50USD
Spread / Average Target
-23.64%

Quarterly revenue - Rate of surprise